Recombinant interferon alfa-2b

Phase 3

Recombinant interferon alfa-2b is one of 14 therapeutic programs targeting Clinical Stage III Cutaneous Melanoma AJCC v8. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Clinical Stage III Cutaneous Melanoma AJCC V8Active, not recruiting

Malignant MelanomaActive, not recruiting

Melanoma of Unknown PrimaryActive, not recruiting

Clinical Stage III Cutaneous Melanoma AJCC V8Phase 3

Active, not recruiting

Malignant MelanomaPhase 2

Active, not recruiting

Melanoma of Unknown PrimaryPhase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Clinical Stage III Cutaneous Melanoma AJCC V8

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

2 2

Yervoy

Bristol-Myers Squibb

Phase 3

2 3

Keytruda

Merck & Co.

Phase 3

1 4

Tecentriq

Roche

Phase 2

1 5

Dabrafenib Mesylate

NNational Cancer Institute (NCI)

Phase 3

1 6

Cometriq

EExelixis

Phase 2

1 7

Avastin

BBio-Thera Solutions

Phase 2

1 8

Trametinib Dimethyl Sulfoxide

NNational Cancer Institute (NCI)

Phase 3

1 9

Recombinant interferon alfa-2b

SSt. Jude Children's Research Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Clinical Stage III Cutaneous Melanoma AJCC V8

NCT02506153

Phase 3Active, not recruiting

Melanoma of Unknown Primary

NCT01274338

Q2 2031

Phase 2Active, not recruiting

Malignant Melanoma

NCT00539591

Clinical

Trials by Indication[1]

Melanoma of Unknown Primary1 trial

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01274338·1,673 enrolled

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02506153·1,301 enrolled

Malignant Melanoma1 trial

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT00539591·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Recombinant interferon alfa-2b. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Recombinant interferon alfa-2b. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSt. Jude Children's Research Hospital

Recombinant interferon alfa-2b

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2031

Trials by Indication[1]

Melanoma of Unknown Primary1 trial

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

Malignant Melanoma1 trial

References

Drug Info

Quick Facts

Related News